Related Experiment Videos
B cell depletion in autoimmune disease
Claire Gorman1, Maria Leandro, David Isenberg
1Centre for Rheumatology, The Middlesex Hospital, University College London, UK.
Arthritis Research & Therapy
|June 8, 2004
Summary
Rituximab, a chimeric monoclonal antibody targeting the CD20 cell marker, effectively depletes B cells. This approach shows promise for treating autoimmune diseases like rheumatoid arthritis and lupus erythematosus.
Area of Science:
- Immunology
- Rheumatology
- Oncology
Background:
- The CD20 cell marker is present on B cells during early development.
- Rituximab, a monoclonal antibody targeting CD20, is approved for B cell non-Hodgkin's lymphoma.
Purpose of the Study:
- To review the efficacy of CD20-targeted B cell depletion using rituximab in autoimmune diseases.
- To explore rituximab's therapeutic potential beyond its approved indications.
Main Methods:
- Review of clinical data and experimental studies on rituximab treatment.
- Focus on B cell depletion strategies utilizing anti-CD20 antibodies.
Main Results:
- Rituximab has been successfully used to treat chronic idiopathic thrombocytopaenia.
- Significant success has been observed in patients with rheumatoid arthritis and systemic lupus erythematosus.
Conclusions:
- B cell depletion via rituximab is a viable therapeutic strategy for certain autoimmune conditions.
- Further research into rituximab's application for B cell-mediated pathologies is warranted.